Congenital disorders of glycosylation are a family of more than two hundred inherited diseases in which protein glycosylation is disrupted, leading to diverse multisystem symptoms and, too often, no approved therapies. SRD5A3-CDG is among the rarest subtypes, with approximately 60 cases reported to date, and causes ataxia, developmental delay, and visual impairment through a defect in dolichol biosynthesis, the lipid backbone on which N-glycans are assembled. A Communications Medicine study reports that atorvastatin, a cholesterol-lowering statin already taken by millions, improves disease-relevant phenotypes in a worm model and partially corrects the polyprenol-to-dolichol imbalance in fibroblasts from SRD5A3-CDG patients. The study illustrates how Glycomics Assays and model-organism screening can converge on an off-patent therapy for an orphan disease.

Introduction

Dolichol is an essential lipid carrier. In the endoplasmic reticulum it anchors the lipid-linked oligosaccharide that is transferred en bloc to nascent proteins, the first step of almost all N-glycosylation. SRD5A3 encodes a polyprenal reductase that catalyzes the conversion of polyprenal to dolichal in the multi-step polyprenol-to-dolichol pathway. When the enzyme fails, polyprenol and polyprenal accumulate; in patient fibroblasts, dolichol levels remain comparable to controls, whereas in the worm model dolichol is significantly reduced. In both settings, the polyprenol-to-dolichol ratio rises, and phosphorylated polyprenol competes with dolichol-phosphate as a lipid carrier, so that immature glycans are transferred onto proteins instead of mature ones. The result is widespread glycosylation stress across tissues, which explains the disease's neurological and ocular breadth.

Despite the clarity of the biochemistry, therapy has lagged because no animal model was tractable for screening. The authors solved that by building a Caenorhabditis elegans model carrying the recurrent patient mutation, then using a motility assay to screen for compounds that restore movement.

Building a Worm Model of SRD5A3-CDG

The worm strain harbors a homozygous nonsense mutation, srdf-3(W6X), at the position corresponding to the most common human pathogenic variant, p.Trp19Ter (W19X). These animals show developmental delay, neuronal dysfunction, and metabolic shifts consistent with disruption of the mevalonate pathway, the isoprenoid-producing route that feeds both cholesterol and dolichol synthesis. Because worms are small, inexpensive, and amenable to automated imaging, their movement could be recorded automatically for ten-hour windows, enabling a high-throughput phenotypic screen that mammalian models could not support.

That screen surfaced several compound classes that improved motility, and a structure-activity analysis pointed to a shared mevalonate pharmacophore. The most familiar hit was atorvastatin, an HMG-CoA reductase (HMGR) inhibitor that blocks the rate-limiting step of the mevalonate pathway. At first glance a statin worsening an already impaired pathway sounds counterintuitive, but the data told a subtler story about pathway rebalancing rather than simple blockade.

Atorvastatin Restores the Polyprenol-to-Dolichol Ratio

In patient-derived fibroblasts, SRD5A3 deficiency skews the polyprenol-to-dolichol ratio toward polyprenol. Treatment with a low dose of atorvastatin (0.1 μM) lowered total polyprenols and shifted the polyprenol-to-dolichol ratio back toward normal in three of four patient lines (15–40% reduction), although the change did not reach statistical significance (p = 0.08). This is the key mechanistic claim: the drug does not replace the missing enzyme, but reduces polyprenol accumulation, thereby easing the competition between polyprenol-phosphate and dolichol-phosphate during lipid-linked oligosaccharide assembly.

The result reframes statins as pathway modulators, not just cholesterol-lowering pills. Glycan Profiling of the treated fibroblasts would be the natural next readout, asking whether the improved ratio translates into more mature N-glycans on patient proteins. The study establishes the principle; quantitative glycoproteomics can confirm it at the glycan level.

Notably, the response was dose-dependent and system-specific. In worms, atorvastatin rescued the reduced progeny phenotype only at low dose (0.1 μM) and was toxic at 50–100 μM, and it improved neuronal and paralysis phenotypes without significantly altering polyprenol or dolichol levels—suggesting that phenotypic rescue in C. elegans may act through prenylation, ubiquinone, or mitochondrial maintenance rather than through the polyprenol-to-dolichol balance itself. Only in human fibroblasts did the ratio move. This context-dependence underscores that partial, carefully titrated flux reduction—not pathway shutdown—is the therapeutic principle.

Fig. 1 Atorvastatin rescues disease-relevant phenotypes in W6X worms and trends toward rebalancing polyprenol-to-dolichol ratios in patient fibroblasts. (Daghar, et al., 2026)

Why Glycosylation Defects Are Hard to Treat

Most CDGs are caused by enzyme deficiencies in glycosylation or its lipid supports, so the intuitive therapy is substrate or enzyme replacement. Both are hard here: dolichol is a hydrophobic, poorly delivered lipid, and enzyme replacement would require correcting every cell. A small molecule that reprograms upstream metabolism is far more deliverable, which is why a repurposed statin is attractive despite its indirect mechanism.

The work also underscores how central Glycoproteomics is to CDG research. Demonstrating therapeutic benefit ultimately means showing that patient proteins regain proper glycosylation, not merely that a metabolite ratio improves. Site-specific N-Glycan Profiling of treated fibroblasts is the decisive validation, converting a motility rescue in worms into evidence of corrected human glycosylation.

A Template for Rare-Disease Discovery

Beyond SRD5A3-CDG, the study offers a method: combine a patient-relevant model organism with a phenotypic screen, then validate hits in human cells. This worm-to-fibroblast pipeline compresses the early part of drug discovery and is especially suited to rare diseases that cannot justify massive bespoke programs. Atorvastatin's established safety record in adults and children means that, if glycan-level rescue is confirmed, it could move toward clinical consideration faster than a novel molecule.

The approach also generalizes to other dolichol-pathway CDGs, where similar metabolic rebalancing might help, and to other approved drugs that modulate isoprenoid flux. Sialic Acid Analysis and other linkage-resolved assays would track whether rescued glycosylation recovers the terminal modifications patients lack, a finer question than bulk glycan abundance.

Measuring Success at the Glycan Level

For CD BioGlyco, the paper is a reminder that CDG therapeutics will ultimately be judged by glycosylation readouts. A drug that fixes a ratio but not a glycan is incomplete. Glyco-Biomarker Detection built on intact-glycopeptide mass spectrometry can quantify the mature-versus-immature glycan balance in patient samples, providing the endpoint that regulatory agencies will demand.

As more CDG genes are modeled in simple organisms, the bottleneck will shift from finding candidates to proving glycosylation correction. That is a measurement problem, and it is exactly the problem glycobiology service providers exist to solve.

Outlook

Atorvastatin will not be declared a treatment for SRD5A3-CDG tomorrow. The fibroblast rescue is partial and not yet statistically significant, the worm is a proxy, and human dosing for this indication is unexplored—particularly given the narrow dose window between benefit and toxicity. But the direction is encouraging: a drug already in widespread use may modulate the very pathway that fails in this disorder, and the model-cell validation framework is now in place to test it properly. For the broader CDG field, the study suggests that the mevalonate pathway is densely populated with approved drugs whose isoprenoid-flux effects deserve systematic, glycan-level evaluation.

Related Services & Products

• Glycan Release Service
• Glycan Separation and Purification Service
• Glycan Derivation Service
• Glycomic Quantitation
• Glycoprotein Enrichment
• Glycoprotein Quantification
• Glycoprotein Structure Analysis
• Custom Glycosylation Service

Reference

1. Daghar, H., et al. (2026). Repurposing the HMG-CoA reductase inhibitor atorvastatin for SRD5A3-congenital disorder of glycosylation. Communications Medicine. DOI: 10.1038/s43856-026-01791-4.